Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Aug 2020
Multicenter StudyPhase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
Tepotinib (MSC2156119J) is an oral, potent and highly selective small molecule mesenchymal-epithelial transition factor (MET) inhibitor for which the recommended Phase II dose of 500 mg once daily has been defined, based on the first-in-man trial conducted in the USA and Europe. We carried out a multicenter Phase I trial with a classic `3 + 3' design to determine the recommended Phase II dose in Japanese patients with solid tumors (NCT01832506). ⋯ These results, including initial signals of antitumor activity, support further development of tepotinib in Japanese patients with cancer.
-
Jpn. J. Clin. Oncol. · Aug 2020
Effects of the publication of Clinical Guidelines for the Management of Chemotherapy-Induced Peripheral Neuropathy on the Administration Preferences of Oncology Specialists: Japanese Association of Supportive Care in Cancer.
We conducted a questionnaire survey of oncology specialists to investigate the frequency of administration of different drugs for the management of chemotherapy-induced peripheral neuropathy in Japan in 2015. Our group published Clinical Guidelines for the Management of Chemotherapy-Induced Peripheral Neuropathy in 2017 (CIPN-GL2017). In these guidelines, we recommended duloxetine only. To verify the effect of the publication of the CIPN-GL2017, we conducted a questionnaire survey in 2019. ⋯ It is possible that the publication of CIPN-GL2017 influenced administration preferences of oncology specialists.